OncoDaily

Where the global cancer community meets - daily news, trial breakdowns. KOL interviews, live from major cancer congresses
OncoDaily - The Voice of Oncology

[OncoDaily @oncodaily]

OncoDaily is at #ASCO26 ! Join us and let the community know how your @ASCO is going.

1. Tag us in your posts
2. Reach out to these people and ask how you can get involved
3. Send us about your experience

Let’s get started!

#OncoDaily

[OncoDaily @oncodaily]

Honored to Receive ASCO IDEA Award Advancing GI Oncology Across Latin America - Luis Gabriel Parra Lara

@luisgparral @Icesi @FVLCali

https://t.co/cphD3YFfy9

#OncoDaily #ASCO

[OncoDaily @oncodaily]

Every Cancer Patient Deserves Access to Quality Care at the Right Time - Puneet Sharma

@Cancer24x7onX

https://t.co/2PJpvpduvK

[OncoDaily @oncodaily]

Critical Updates on Pancreatic Cancer and Biliary Tract Cancer | ASCO 2026

Dr. Benjamin Weinberg, GI Medical Oncologist at Ruesch Center Lombardi Comprehensive Cancer Center, Georgetown University, highlights three important studies presented at #ASCO26 focusing on pancreatic cancer and biliary tract cancer.

He discusses the X-PEL-PANC trial, which evaluated BXCL701 combined with pembrolizumab in metastatic pancreatic cancer and demonstrated encouraging responses, including in microsatellite-stable disease. The study also revealed promising immune activation within the tumor microenvironment.

Dr. Weinberg also reviews results from the PROGEM trial, which investigated proglumide as a stromal-modifying agent designed to reduce fibrosis and improve immune cell infiltration in pancreatic tumors.

Finally, he summarizes findings from a second-line biliary tract cancer study evaluating nanoliposomal irinotecan plus 5-FU/leucovorin, a regimen now incorporated into NCCN Guidelines, while discussing its benefits and toxicity considerations.

@benweinbergmd

https://t.co/nCBkwzC4xn

[OncoDaily @oncodaily]

There is No Longer Such Thing as an 'Undruggable' Target - Douglas Flora

@dougflora2

https://t.co/vGbI96PGTp

[OncoDaily @oncodaily]

How Social Media is Changing Oncology | Dr. Enes Erul

Dr. Enes Erul, Medical Oncology Fellow at Ankara University and member of the ASCO Health Policy Group, discusses the BRINC-ONC study - an initiative exploring how oncologists engage with social media.

The study examines motivations for social media use, concerns surrounding misinformation, how physicians respond to inaccurate health information online, and whether conflict-of-interest disclosures are consistently communicated in digital spaces.

The findings aim to help inform future policies and recommendations regarding social media use, digital professionalism, transparency, and physician engagement in online healthcare discussions.

Dr. Erul invites oncology professionals worldwide to participate and contribute to this important research effort.

@ErulEnes

https://t.co/Oujr8BomG1

[OncoDaily @oncodaily]

Thanks to Ali Velshi for Having Me to Discuss the Latest Breakthrough in Pancreatic Cancer - Shubham Pant

@AliVelshi

https://t.co/2TfAJPAM0I

[OncoDaily @oncodaily]

Beyond the Cure: The New Focus on Cancer Survivorship | ASCO 2026

Dr. Catarina Ribeiro, Medical Oncologist and Medical Director at Syneos Health, shares her key takeaways from #ASCO26 and highlights the major trends shaping the future of oncology.

She discusses three transformative themes emerging from this year's meeting: exciting advances in novel therapies such as KRAS-targeted treatments, bispecific and trispecific antibodies; the growing integration of artificial intelligence and technology into drug development; and evolving approaches to treatment response assessment, including the expanding role of measurable residual disease (MRD) concepts in solid tumors.

Dr. Ribeiro also emphasizes a broader shift toward cancer survivorship, where treatment effectiveness must be balanced with long-term safety, quality of life, and minimizing treatment burden for patients.

@catarinaribeira

https://t.co/Sm69LLRKJv

[OncoDaily @oncodaily]

What a Wonderful Experience at My 3rd ASCO Annual Meeting! - Elen Baloyan

@Elen_Baloyan

https://t.co/RLfqT9LjLY

[OncoDaily @oncodaily]

Picture Health - Rhea Chitalia Presents ASCO 2026 Findings on QVT Score and Anti-Angiogenic Therapy Benefit

@PictureHealthAI

https://t.co/xiQOqgWiol

#OncoDaily #ASCO2026

[OncoDaily @oncodaily]

ASCO 2026: Dr. Daniel V. Araujo the Latest GU Oncology Breakthroughs

Dr. Daniel Araujo, GU Medical Oncologist at the University of Florida, UF Health Cancer Institute, discusses research presented at #ASCO26 examining how access to subsequent lines of therapy may influence overall survival outcomes in first-line oncology trials.

The study analyzed randomized clinical trials across prostate, lung, and breast cancer to determine how often patients in control arms received the investigational drug or a similar therapy after disease progression.

The findings revealed that many patients never received effective later-line treatments, raising important questions about how clinical trial outcomes are interpreted, particularly in global studies where access to therapies may vary significantly.

Dr. Araujo explains the implications for targeted therapies, immunotherapy, trial design, and healthcare equity, emphasizing the need for transparent reporting and improved access to treatment worldwide.

@DVAraujoMD

https://t.co/xu74UiagO3

[OncoDaily @oncodaily]

Bishal Gyawali Expresses What We Patients Have Been Saying for Years - Kelly Shanahan

@stage4kelly @oncology_bg

https://t.co/Od3qkKtwv3

[OncoDaily @oncodaily]

Why Liquid Biopsy is a Game-Changer in Oncology!

Dr. Roberto Borea, Medical Oncologist at The Ohio State University and Chair of the Young Committee of the International Society of Liquid Biopsy (ISLB), shares an overview of the society's mission and opportunities for researchers, clinicians, and trainees.

In this interview from #ASCO26, Dr. Borea highlights the growing role of liquid biopsy in oncology, previews the upcoming ISLB Annual Conference in Madrid, and discusses travel grants, abstract submissions, educational initiatives, podcasts, and networking opportunities.

He also explains how society members can collaborate with internationally recognized leaders in the field and contribute to advancing research and clinical applications of liquid biopsy technologies.

@RobertoBoreaMD

https://t.co/aO1mjkzehO

[OncoDaily @oncodaily]

36 Posts Not To Miss From 2026 ASCO Week

The ASCO 2026 Annual Meeting in Chicago has officially come to an end, leaving the oncology community with a massive wave of new data, practice-changing updates, and a clearer plan for patient care worldwide. From the remarkable survival results shared during the Sunday Plenary sessions to critical discussions on safely reducing treatment intensity, this year’s meeting showed that cancer care is advancing rapidly.

As clinicians and researchers head home to process these updates and apply them to daily practice, here is a comprehensive look back at the main trials, major tumor tracks, and standout moments that defined this important week.

https://t.co/7mO6ElXnKD

#OncoDaily #ASCO26

[OncoDaily @oncodaily]

Congratulations to My Friend and Partner, Matthew Kurian for the Representation - Douglas Flora

@dougflora2 @MatthewKurianMD

https://t.co/24tlv1eHYc

[OncoDaily @oncodaily]

Gastric Cancer: No Chemotherapy, No Surgery? | Dr. Thomas Samaille

During #ASCO26, Dr. Thomas Samaille from Saint Antoine Hospital, presented the updated long-term results of the NEONIPIGA study on behalf of Professor André and the GERCOR multidisciplinary team.

The phase II trial evaluated neoadjuvant dual immunotherapy with nivolumab and ipilimumab in patients with localized, resectable dMMR/MSI gastric cancer. Given the known sensitivity of MSI tumors to immunotherapy and their reduced responsiveness to chemotherapy, the study explored whether chemotherapy could safely be omitted.

The long-term results demonstrate excellent event-free survival and overall survival outcomes, supporting the use of dual immunotherapy without chemotherapy in this patient population.

Dr. Samaille also discusses the ongoing DAVY trial, which is investigating an even more ambitious question: whether surgery may be avoided in selected patients who achieve deep responses to immunotherapy.

https://t.co/FxxdpVPBYA

[OncoDaily @oncodaily]

@stage4kelly @oncology_bg We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
https://t.co/Od3qkKtwv3

[OncoDaily @oncodaily]

Honored to Receive the Most Engaged Working Group Award at @ASCO 2026 - @Noha_Soror

https://t.co/eiAQROAjMs

[OncoDaily @oncodaily]

The Best Way to Thank Our Mentors is to Become One - @MatthewKurianMD

https://t.co/R4JNy3uxnb

[OncoDaily @oncodaily]

The True Meaning of Mentorship in Global Oncology | Dr. Katherine Van Loon

Dr. Katherine Van Loon, gastrointestinal oncologist, professor at UCSF, and recipient of the 2026 Conquer Cancer Foundation Women Who Conquer Cancer Mentorship Award, reflects on the meaning of mentorship and its role in shaping the future of global oncology.

In this video, Dr. Van Loon shares the emotional story of learning she had received the award, the international community of mentees who nominated her, and the values that guide her mentorship philosophy.

She discusses the importance of empowerment, impact-driven work, individualized training pathways, and building lasting relationships with mentees. Drawing on years of experience in global oncology, she explains why there is no one-size-fits-all model for training and leadership development.

@KVanLoonMD

https://t.co/oFoesjFG1x

[OncoDaily @oncodaily]

15-Year Final Outcomes of the SOFT and TEXT Trials in Premenopausal Breast Cancer - Professor Kefah Mokbel

@KefahMokbel

https://t.co/vh4S7jbIe8